Aerin Medical

Executive Summary

Aerin Medical is a privately held medical device company based in Sunnyvale, California, focused on non-invasive, office-based treatments for chronic nasal conditions using proprietary temperature-controlled radiofrequency (RF) technology. Its two lead products—VivAer Stylus for nasal airway obstruction (NAO) and RhinAer Stylus for chronic rhinitis—offer lasting symptom relief with minimal downtime, addressing significant unmet needs in the ENT market. The company has established a growing commercial presence in the US, leveraging favorable reimbursement trends and positive physician adoption. While specific financials and funding details are not publicly available, Aerin’s focused product portfolio and differentiated technology position it as a potential acquisition target or IPO candidate in the medtech space. Key near-term drivers include expanding clinical evidence, potential FDA clearances for additional indications, and scaling commercial operations to capture market share in the large, underserved population suffering from chronic nasal conditions.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for next-generation VivAer or RhinAer device with enhanced features75% success
• TBDPublication of pivotal clinical study data demonstrating superiority over standard of care60% success
• TBDStrategic partnership or acquisition by a larger ENT/rhinology-focused medical device company50% success